Other current approaches, such as biologic agents antagonizing proinflammatory cytokines (e.g., IL-6) or the ones that favour increased levels of the suppressive cytokine IL-10, did not result in a substantial reduction of IBD disease activity in clinical trials [6]. The gene discussed is IL10; the disease is inflammatory bowel disease.